Lv1
40 积分 2021-06-04 加入
High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial
3个月前
已完结
Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma
4个月前
已完结
Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial
4个月前
已完结
The Fanconi anemia pathway induces chromothripsis and ecDNA-driven cancer drug resistance
4个月前
已完结
Artificial Intelligence and Chromothripsis
4个月前
已完结
BCL2 inhibition for multiple myeloma and AL amyloidosis
4个月前
已完结
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
4个月前
已完结
Venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed or refractory multiple myeloma (BELLINI): final overall survival results from a randomised, phase 3 study
4个月前
已完结
皖公网安备34019202002308
